C2N Diagnostics is expanding access to blood-based biomarker tests for Alzheimer's disease across Latin America and the Caribbean through a partnership with SouthGenetics. The Precivity portfolio measures brain amyloid pathology to support earlier clinical assessment in regions with limited neuroimaging infrastructure and specialist capacity.
Key Points
- Blood tests detect amyloid pathology before cognitive decline emerges
- Expansion addresses geographic gaps in dementia diagnostic capacity
- Partnership enables earlier treatment decisions for disease-modifying therapies
Longevity Analysis
Early detection of Alzheimer's pathology through accessible blood biomarkers represents a critical intervention point before irreversible neurodegeneration progresses. In regions where PET imaging and dementia specialists remain scarce, validated blood tests shift the diagnostic burden from expensive infrastructure to scalable laboratory capacity—allowing clinicians to identify candidates for emerging disease-modifying treatments before cognitive symptoms manifest. This expands the window for neuroprotection and addresses a fundamental barrier to intervention: the inability to detect pathology in populations where it matters most.
Original published by LT Wire.